KILN
28.11.2022 10:01:42 CET | Business Wire | Press release
Today, Kiln announced the close of an €17 million financing round to expand their market-leading staking infrastructure product range. Kiln, the leading enterprise-grade staking technology provider, with over $500 million1 of assets staked under management, received funding from Illuminate Financial with participation by a number of leading crypto investing groups including Consensys, GSR, Kraken Ventures, Leadblock Partners, Sparkle Ventures, XBTO and renewed participation from existing investors 3KVC, Blue Yard Capital, SV Angel and Alven among others.
Kiln believes that the staking market is becoming institutionalized and must move beyond running validators to meet the growing customer need to spread risk. This means creating validator-agnostic APIs and services to enable multi-provider staking. This in turn enables digital assets to be staked wherever they are held, for wallets, custodians, and exchanges. As the industry evolves and the need to integrate multiple staking players proves real, Kiln is in an ideal position to play the aggregator role and accelerate it.
Following the Ethereum network’s transition to a Proof of Stake (PoS) consensus (The Merge) in September, which significantly de-risked the protocol roadmap, Kiln predicts the demand for staking ETH to grow exponentially. Currently, only 12.5%2 of ETH supply is staked, compared to 50-80% for other PoS assets. Plus, with an annual percentage yield on ETH in the 6-7%3 range since the Merge, it offers an attractive return-rate for investors.
Staking is the Web3 industry’s native yield: the yield comes from helping secure the blockchain (validating and proposing blocks), and there is no counterparty risk as in lending, or when dealing with a third-party intermediary such as a centralised exchange.
Laszlo Szabo - Co-Founder & CEO at Kiln, said: “I am thrilled to close a robust funding round with such respected investors in the crypto space which will enable us to build out the next generation market standard in staking technology. At Kiln, we believe it is critical to provide enterprise-grade infrastructure to institutional users, that in turn enables our customers to create new opportunities for their users. We thank our existing and new investors for their partnership. The Kiln team couldn't be more excited about this next stage of building out a world-class staking stack.”
The funding, which includes €17 Million in Series A, will be used to add new features to Kiln’s industry leading product range. Kiln already offers the largest product range dedicated to staking on the market with its focus as a technology provider delivering a simple and validator-agnostic staking stack. This includes:
- Kiln Connect, which provides a single SDK to integrate staking, rewards data, and your custodian on all major PoS blockchains
- Kiln On-Chain, which provides smart contracts for seamless ETH staking, any amount of ETH and automated rewards management
- Kiln Dashboard, which provides a 1-click staking dashboard, administration interface, reporting and data exporting
- Kiln Validators, a suite of dedicated or shared validators, with enterprise-grade SLAs, deployed on our multi-cloud Kubernetes infrastructure
Kiln’s customers include industry-leading companies such as Binance US, GSR and Ledger.
Rezso Szabo, Partner at Illuminate Financial, said: "We are witnessing a once in a generation change that will catalyze the institutionalisation of Digital Assets. Sophisticated users and institutions need enterprise grade infrastructure. As a thesis-driven investor backed by traditional financial institutions, we believe the Kiln team has demonstrated they can build key infrastructure that is critical for both digital assets native institutions and will also serve as the future rails for financial services infrastructure. We are excited to partner with such a high-calibre team, who are on a mission to raise the bar in B2B infrastructure for the whole ecosystem."
Ciaran O'Leary, Co-Founder and General Partner of BlueYard Capital, added: “Staking is going to be one of the core fabrics of the entire crypto industry. Kiln’s robust, scalable and safe solutions provide an important fabric for large pools of capital to participate in the core functioning of crypto networks and to generate novel forms of yield. We are excited that Kiln is at the forefront of this new market.”
Benoît Bosc, GSR Global Head of Product, said: “Having used Kiln’s infrastructure to stake our own treasury and in the future to offer to our clients, our company’s missions are perfectly aligned. We are delighted to be able to participate in the next stage of Kiln’s development and to contribute to making staking easier and more accessible to everyone.”
Kiln’s unique team is made up of globally recognized experts in the areas of SaaS, blockchain infrastructure and smart contracts. The company is led by its three co-founders: CEO Laszlo Szabo, a serial entrepreneur who was previously the co-founder of tech recruitment firm Skill Hunter and has been accelerating Web3 adoption since 2017, CPO Ernest Oppetit, a former product manager at Improbable and Qubit; and COO Thomas de Phuoc, who was previously the Country Lead for France at Circle.
Kiln comprises industry leaders including Duncan Hoffman, VP Revenue, who previously led the EMEA region for Chainalysis as General Manager and scaled the business through years of growth that led to an $8.6B valuation. Duncan helped establish Chainalysis as the largest SaaS company in the Web3 industry and market-leading solution for cryptocurrency compliance and investigation use cases to help build trust in blockchains.
1 |
Total as of 11.23.2022 |
2 |
As of 11.23.2022 Source: https://beaconcha.in/ and https://etherscan.io/stat/supply |
3 |
Source Rated.network |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005157/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
